Shots:

• The companies collaborated to evaluate the safety and preliminary efficacy of Werewolf's WTX-124 as monothx. or in combination with Merck’s Keytruda (anti-PD-1 therapy) in a P-I trial for patients with solid tumors
• The company plans to submit an IND application for WTX-124 to the US FDA in H2’22
• WTX-124 is a systemically delivered- conditionally activated IL-2 INDUKINE molecule engineered to minimize the severe toxicities that have been identified with recombinant IL-2 therapy & maximize clinical benefit when used in combination with checkpoint inhibitors in multiple tumor types

  Ref: Globe Newswire | Image: Merck